A biopharmaceutical company developing innovative treatments for serious chronic metabolic diseases.
About
POXEL SA is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases with a metabolic pathophysiology. Their primary areas of focus include metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases. The company announced a new Tranche D PDR subscription agreement with IPF Partners on March 25, 2026.
Tags
Performance
Company Timeline
No timeline data for this period
Score Breakdown
47Traction
39Team
0Visibility
11Profile
0Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does POXEL do?
POXEL SA is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases with a metabolic pathophysiology. Their primary areas of focus include metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases. The company announced a new Tranche D PDR subscription agreement with IPF Partners on March 25, 2026.
How much funding has POXEL raised?
POXEL has raised a total of $4M in funding. The most recent round on record is Tranche D PDR Bond Issue.
Where is POXEL headquartered?
POXEL is headquartered in Lyon, France.
When was POXEL founded?
POXEL was founded in 2006.
What industry does POXEL operate in?
POXEL operates in Biotechnology, Pharmaceuticals, Healthcare.